Lenka Munoz

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. pmc A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model
    Lenka Munoz
    Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E Chicago Ave, Mailcode W896, Chicago, IL 60611, USA
    J Neuroinflammation 4:21. 2007
  2. doi request reprint Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
    Lenka Munoz
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia
    Neuropharmacology 58:561-8. 2010
  3. pmc Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits
    Wenhui Hu
    Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E Chicago Avenue, Mail Code W896, Chicago, IL 60611, USA
    Bioorg Med Chem Lett 17:414-8. 2007
  4. doi request reprint Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase
    Lenka Munoz
    Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
    Anal Biochem 401:125-33. 2010
  5. doi request reprint Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle
    Lenka Munoz
    Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sydney, NSW, Australia
    Eur J Pharmacol 635:212-8. 2010
  6. doi request reprint p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
    Yiu To Yeung
    Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia
    J Neurooncol 109:35-44. 2012

Collaborators

Detail Information

Publications6

  1. pmc A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model
    Lenka Munoz
    Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E Chicago Ave, Mailcode W896, Chicago, IL 60611, USA
    J Neuroinflammation 4:21. 2007
    ....
  2. doi request reprint Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
    Lenka Munoz
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia
    Neuropharmacology 58:561-8. 2010
    ..Thus, we present here an update on the role of p38 MAPK in neurodegeneration, with a focus on Alzheimer's disease, by summarizing recent literature and several key papers from earlier years...
  3. pmc Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits
    Wenhui Hu
    Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E Chicago Avenue, Mail Code W896, Chicago, IL 60611, USA
    Bioorg Med Chem Lett 17:414-8. 2007
    ..The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders...
  4. doi request reprint Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase
    Lenka Munoz
    Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
    Anal Biochem 401:125-33. 2010
    ....
  5. doi request reprint Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle
    Lenka Munoz
    Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sydney, NSW, Australia
    Eur J Pharmacol 635:212-8. 2010
    ..The anti-inflammatory activity is equivalent to the prototypical p38 MAPK inhibitor SB203580. Our results implicate a future pharmacotherapeutic strategy towards reducing inflammation in asthma and airway remodelling...
  6. doi request reprint p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
    Yiu To Yeung
    Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia
    J Neurooncol 109:35-44. 2012
    ..Importantly, p38 MAPK inhibition strongly reduced invasion of U251 glioblastoma cells in an inflammatory microenvironment, providing evidence for a p38 MAPK-regulated link between inflammation and invasiveness in GBM pathophysiology...